Efficacy and safety profile of the potent and selective bradykinin B2 receptor antagonist icatibant in healthy volunteers

被引：0
|
作者：
Rosenkranz, B.
Brunner-Ferber, F.
Knolle, J.
机构：
[1] Jerini AG, Berlin, Germany
[2] Brunner Naga, Hlth Sci Consulting, Zurich, Switzerland
来源：
ALLERGY | 2007年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：308 / 308
页数：1
相关论文
共 50 条
  • [41] Proof-of-concept study of icatibant (JE 049), a bradykinin B2 receptor antagonist in treatment of hereditary angioedema.
    Rosenkranz, B
    Bork, K
    Frank, J
    Kreuz, W
    Dong, L
    Knolle, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P14 - P14
  • [42] Nonpeptide bradykinin B2 receptor antagonists:: Conversion of rodent-selective bradyzide analogues into potent, orally-active human bradykinin B2 receptor antagonists
    Dziadulewicz, EK
    Ritchie, TJ
    Hallett, A
    Snell, CR
    Davies, JW
    Wrigglesworth, R
    Dunstan, AR
    Bloomfield, GC
    Drake, GS
    McIntyre, P
    Brown, MC
    Burgess, GM
    Lee, W
    Davis, C
    Yaqoob, M
    Phagoo, SB
    Phillips, E
    Perkins, MN
    Campbell, EA
    Davis, AJ
    Rang, HP
    JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (11) : 2160 - 2172
  • [43] Self-administration of a novel subcutaneous bradykinin b2 receptor antagonist, icatibant, as an effective treatment option in patients with hereditary angioedema
    Santucci S.
    Pham H.
    Harrison R.
    Yang W.
    Allergy, Asthma & Clinical Immunology, 10 (Suppl 2)
  • [44] Novel pharmacotherapy of acute hereditary angioedema with bradykinin B2-receptor antagonist icatibant
    Bas, M.
    Bier, H.
    Greve, J.
    Kojda, G.
    Hoffmann, T. K.
    ALLERGY, 2006, 61 (12) : 1490 - 1492
  • [45] Icatibant, a Selective Bradykinin-B2 Receptor Antagonist, in Acquired Angioedema Due to C1 Inhibitor Deficiency
    Bork, K.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB100 - AB100
  • [46] Role of kinins in seasonal allergic rhinitis:: Icatibant, a bradykinin B2 receptor antagonist, abolishes the hyperresponsiveness and nasal eosinophilia induced by antigen
    Turner, P
    Dear, J
    Scadding, G
    Foreman, JC
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (01) : 105 - 113
  • [47] Treatment of repeated attacks of hereditary angioedema with bradykinin-B2-receptor antagonist icatibant
    Bork, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2009, 7 : 161 - 162
  • [48] Treatment of laryngopharyngeal and lingual hereditary angioedema with bradykinin-B2-receptor-antagonist icatibant
    Bas, M.
    Greve, J.
    Kojda, G.
    Bier, H.
    Hoffmann, K.
    ALLERGY, 2007, 62 : 95 - 95
  • [49] Synthesis and analysis of potent, more lipophilic derivatives of the bradykinin B2 receptor antagonist peptide Hoe 140
    Kennedy, KJ
    Orwig, KS
    Dix, TA
    Christopher, J
    Jaffa, AA
    JOURNAL OF PEPTIDE RESEARCH, 2002, 59 (04): : 139 - 148
  • [50] In various tumour cell lines the peptide bradykinin B2 receptor antagonist, Hoe 140 (Icatibant), may act as mitogenic agonist
    Drube, S
    Liebmann, C
    BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (08) : 1553 - 1560
12345